Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
Max Planck Society · Max Planck Institute for Dynamics and Self-Organization · +7 more institutions
Abstract
Erythropoietin (EPO) and its receptor play a major role in embryonic brain, are weakly expressed in normal postnatal/adult brain and up-regulated upon metabolic stress. EPO protects neurons from hypoxic/ ischemic injury. The objective of this trial is to study the safety and efficacy of recombinant human EPO (rhEPO) for treatment of ischemic stroke in man.
The trial consisted of a safety part and an efficacy part. In the safety study, 13 patients received rhEPO intravenously (3.3 X 10(4) IU/50 ml/30 min) once daily for the first 3 days after stroke. In the double-blind randomized proof-of-concept trial, 40 patients received either rhEPO or saline. Inclusion criteria were age
Citation impact
- FWCI
- 21.67
- Percentile
- 100%
- References
- 32
Authors
23- HEHannelore EhrenreichCorresponding
Max Planck Society, Max Planck Institute for Dynamics and Self-Organization
- MHMartin Hasselblatt
Max Planck Society, Max Planck Institute for Dynamics and Self-Organization
- CDChristoph Dembowski
Max Planck Society, Max Planck Institute for Dynamics and Self-Organization
- LCLukas Cepek
Max Planck Society, Max Planck Institute for Dynamics and Self-Organization
- PLPiotr Lewczuk
Max Planck Society, Max Planck Institute for Dynamics and Self-Organization
Topics & keywords
- Medicine
- Erythropoietin
- Fluid-attenuated inversion recovery
- Modified Rankin Scale
- Stroke (engine)
- Anesthesia
- Cerebrospinal fluid
- Internal medicine
- Good health and well-being